Products
Pre-made Vudalimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-CTLA4/CTLA-4;PDCD1/PD-1 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-631
Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor's proprietary XmAb® technology) that increases binding affinity to the receptor FcRn.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-631-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-631-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-631-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-631-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody |
| INN Name | Vudalimab |
| Target | CTLA-4;PD-1 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Xencor |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
